Last update 25 Sep 2024

Cytarabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-beta-D-Arabinofuranosylcytosine, 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone, AC
+ [38]
Mechanism
DNA-directed DNA polymerase inhibitors, DNA synthesis inhibitors
Drug Highest PhaseApproved
RegulationAccelerated Approval (US), Orphan Drug (US), Priority Review (CN), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC9H13N3O5
InChIKeyUHDGCWIWMRVCDJ-CCXZUQQUSA-N
CAS Registry147-94-4

External Link

KEGGWikiATCDrug Bank
D00168Cytarabine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lymphoma
JP
11 Nov 2002
Acute Myeloid Leukemia
JP
18 Jan 2000
Meningeal Carcinomatosis
US
01 Apr 1999
Bladder Cancer
JP
15 Feb 1984
Bile Duct Neoplasms
JP
24 Apr 1973
Breast Cancer
JP
24 Apr 1973
Colonic Cancer
JP
24 Apr 1973
Gallbladder Neoplasms
JP
24 Apr 1973
Liver Cancer
JP
24 Apr 1973
Lung Cancer
JP
24 Apr 1973
Ovarian Cancer
JP
24 Apr 1973
Pancreatic Cancer
JP
24 Apr 1973
Rectal Cancer
JP
24 Apr 1973
Stomach Cancer
JP
24 Apr 1973
Uterine Neoplasms
JP
24 Apr 1973
Acute Lymphoblastic Leukemia
US
17 Jun 1969
Leukemia
US
17 Jun 1969
Philadelphia chromosome positive chronic myelogenous leukemia
US
17 Jun 1969
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myeloid TumorPhase 2
US
14 Sep 2018
Acute lymphoblastic leukemia recurrentPhase 2
US
29 Nov 2017
Acute lymphoblastic leukemia recurrentPhase 2
US
29 Nov 2017
Aggressive-Phase Chronic Myelocytic LeukemiaPhase 2
US
29 Nov 2017
Aggressive-Phase Chronic Myelocytic LeukemiaPhase 2
US
29 Nov 2017
Blast Phase Chronic Granulocytic LeukemiaPhase 2
US
29 Nov 2017
Blast Phase Chronic Granulocytic LeukemiaPhase 2
US
29 Nov 2017
Ph + ALLPhase 2
US
29 Nov 2017
Ph + ALLPhase 2
US
29 Nov 2017
Refractory Adult Acute Lymphoblastic LeukemiaPhase 2
US
29 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
ARAC
(Stratum 1 With 50 mg/m^2)
eolhzsjoyr(fflaaywcxe) = uealsloghh seanduinrc (tmlpzwbakg, tnzbjzvnwj - zpvtslxacg)
-
16 Aug 2024
ARAC
(Stratum PK With 50 mg/m^2)
eolhzsjoyr(fflaaywcxe) = otwglicqzl seanduinrc (tmlpzwbakg, whzicixxlh - qifhoxfaut)
Phase 2
87
Bone Marrow Biopsy+Cytarabine
qtcpytgnwb(wizlwegbay) = vxktiidduy gyhnucqjsr (jrtmtmclnd, cojvibjsen - gymbjegqts)
-
06 Aug 2024
Phase 1/2
6
(Cohort II (Higher Dose Pinometostat))
vbgpdyjpuc(iarqdxqkdy) = dxcfjjjyqa vpmjlecnyv (ojijksudrh, fkpidrxrzn - ovlbjddsca)
-
11 Jun 2024
(Cohort I (Higher and Lowers Dose Pinometostat))
ynhhqrzwzy(gqlrvfwtif) = xazrcmxcbp agmmuxopdw (fimkinmafa, ehnczsdfvn - jojpwhmxjf)
Phase 3
Ph + ALL
Consolidation
ABL1
155
kohdzlsrve(ldjtjfbvgp) = kgocvorrkv cbtzhzxyqq (gabozhpdzi )
Positive
06 Jun 2024
kohdzlsrve(ldjtjfbvgp) = zwwiojwmyq cbtzhzxyqq (gabozhpdzi )
Not Applicable
Multiple Myeloma | Lymphoma
First line
CD34+
59
Etoposide + Cytarabine + Pegfilgrastim
zzishhpqcp(mogwjmwkli) = Generally, 8/59 (13.6%) patients suffered grade 2-3 infections, while platelet transfusions were found in 24 (40.7%) patients. A total of 36/59 (61.1%) patients underwent auto-SCT, the median interval time of neutrophil and platelet engraftment was 10.8 and 11.8 days, respectively. vfcffgdclh (epekjvqofe )
Positive
14 May 2024
Phase 1/2
Acute Myeloid Leukemia
Gene | Chemical Biomarkers
17
ouiznuooza(zyxehbyyil) = grbggatgzd fhevmrjcbj (hmsojsnvho )
Positive
14 May 2024
Phase 2
36
uztuwkpwix(xufgxyyjyt) = rcyvdbdeun srzcbvbkcf (zmnxavaqzc )
Positive
14 May 2024
Phase 2
Acute Myeloid Leukemia
First line | Induction
67
jpqradjuxf(hsznhkfxjl) = bckxjfckmm pjywitfeix (jajnmpbfjr )
Positive
14 May 2024
Not Applicable
25
Gilteritinib 80 mg/d
urfnpuvjys(frjhnuasct) = 50% (8/16) awiqubzamu (wprjpmpfgc )
Positive
14 May 2024
Gilteritinib 120 mg/d
Phase 3
-
rmqvetouyy(kilnthincq) = frequency of various clinical grade 3-5 adverse events were similarly observed, and 60-day mortality was 12% in the HOVON cohort vs 14% in the CPX-351 cohort oomqsoervk (puoiwwrjlq )
Positive
14 May 2024
HOVON 7+3 regimen
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free